<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14396">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919475</url>
  </required_header>
  <id_info>
    <org_study_id>AE051-G-13-003</org_study_id>
    <nct_id>NCT02919475</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis</brief_title>
  <acronym>MOVE-RA</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of
      JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are
      receiving background non-biologic disease-modifying anti-rheumatic drug therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving ACR20 response rate at 12 weeks</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving ACR20/50/70 response rate</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Score (DAS) based on hs-CRP (DAS28-CRP)</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations (Ctrough) of JTE-051 in plasma</measure>
    <time_frame>Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>JTE-051 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTE-051</intervention_name>
    <description>Active drug tablets containing JTE-051</description>
    <arm_group_label>JTE-051 Dose 1</arm_group_label>
    <arm_group_label>JTE-051 Dose 2</arm_group_label>
    <arm_group_label>JTE-051 Dose 3</arm_group_label>
    <arm_group_label>JTE-051 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets identical in appearance to the active drug tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of RA prior to the Screening Visit.

          -  Active disease despite ongoing therapy with up to two non-biologic disease-modifying
             anti-rheumatic drugs, including methotrexate at both the Screening and Baseline
             Visits.

          -  Screening hs-CRP â‰¥1.2 x upper limit of normal (ULN).

        Exclusion Criteria:

          -  Prior/current exposure to biologic and/or kinase inhibitor therapy.

          -  Known history or presence of polyneuropathy of any cause and no presence of
             clinically active compression neuropathy, radiculopathy or plexopathy at the
             Screening Visit.

          -  Positive test results for human immunodeficiency (HIV) virus, hepatitis B virus or
             hepatitis C (HCV) virus at the Screening Visit.

          -  Positive drug of abuse and alcohol test results.

          -  History of a clinically-significant infection that required oral antimicrobial or
             antiviral therapy within 8 weeks prior to Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiro Masuda</last_name>
    <role>Study Chair</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoshiro Masuda</last_name>
    <phone>609-919-9570</phone>
    <email>ClinicalTrials@akrospharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akros Pharma Inc.</last_name>
      <email>ClinicalTrials@akrospharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akros Pharma Inc.</last_name>
      <email>ClinicalTrials@akrospharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akros Pharma Inc.</last_name>
      <email>ClinicalTrials@akrospharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akros Pharma Inc.</last_name>
      <email>ClinicalTrials@akrospharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 28, 2016</lastchanged_date>
  <firstreceived_date>September 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JTE-051</keyword>
  <keyword>Active Rheumatoid Arthritis</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
